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Abstract
In June 2011, the Joint United Nations Programme on HIV/AIDS, the US President’s Emergency 
Plan for AIDS Relief (PEPFAR), and other collaborators outlined a transformative plan to 
virtually eliminate pediatric AIDS worldwide. The ambitious targets of this initiative included a 
90% reduction in new pediatric HIV infections and a 50% reduction in HIV-related maternal 
mortality—all by 2015. PEPFAR has made an unprecedented commitment to the expansion and 
improvement of prevention of mother-to-child HIV transmission (PMTCT) services globally and 
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is expected to play a critical role in reaching the virtual elimination target. To date, PEPFAR has 
been instrumental in the success of many national programs, including expanded coverage of 
PMTCT services, an enhanced continuum of care between PMTCT and HIV care and treatment, 
provision of more efficacious regimens for antiretroviral prophylaxis, design of innovative but 
simplified PMTCT approaches, and development of new strategies to evaluate program 
effectiveness. These accomplishments have been made through collaborative efforts with host 
governments, United Nations agencies, other donors (eg, the Global Fund for AIDS, Tuberculosis, 
and Malaria), nongovernmental organizations, and private sector partners. To successfully meet the 
ambitious global targets to prevent new infant HIV infections, PEPFAR must continue to leverage 
the existing PMTCT platform, while developing innovative approaches to rapidly expand quality 
HIV services. PEPFAR must also carefully integrate PMTCT into the broader combination 
prevention agenda for HIV, so that real progress can be made toward an “AIDS-free generation” 
worldwide.
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Since President George W. Bush launched the President’s Emergency Plan for AIDS Relief 
(PEPFAR) in 2003, global efforts to prevent mother-to-child HIV transmission (PMTCT) 
have undergone a tremendous evolution. A number of affordable and effective interventions 
are now available to protect HIV-exposed infants from infection—the result of a remarkable 
chain of incremental discoveries in HIV prevention science. Service coverage has expanded 
rapidly, made possible by unprecedented donor and national government investments in 
health care delivery infrastructure and by the rapid adoption of new science into 
international policy. With increasing focus on integration of services, gains from PMTCT 
program investments have also begun to extend beyond the prevention of perinatal HIV 
transmission to broader improvements in maternal and child survival. These critical 
developments make it possible to virtually eliminate new pediatric HIV infections globally,1 
a goal which seemed inconceivable only a decade ago. In this report, we review the scientific 
and public health advances made over the past decade and discuss the priority areas that 
PEPFAR and others will need to support to realize these ambitious PMTCT goals.
THE FRAMEWORK FOR PEPFAR’S PMTCT RESPONSE
Although several programs—most notably, UNICEF PMTCT pilot programs (UNICEF), 
Call-to-Action (Elizabeth Glaser Pediatric AIDS Foundation), MTCT-Plus Initiative 
(Columbia University-led consortium), and the U.S. International Mother and Child HIV 
Prevention Initiative (US government)—began supporting PMTCT globally before 2003, the 
launch of PEPFAR accelerated these early efforts. Fifteen “focus countries” (chosen to 
represent the areas most severely affected by HIV) were supported under the original 
authorization, an emergency response designed to stem the tide of the epidemic. As part of 
PEPFAR’s 2008 re-authorization, support expanded to cover 36 countries and regions, as 
program priorities shifted from an emergency response to one that emphasizes strengthening 
health systems and fostering sustainability in the context of ongoing scale-up (Fig. 1).
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PEPFAR’s comprehensive PMTCT response is aligned with the 4-pronged strategy 
articulated by the World Health Organization (WHO) as follows2: (1) prevention of HIV 
infection among women of childbearing age; (2) prevention of unintended pregnancies 
among those living with HIV; (3) prevention of HIV transmission from infected mothers to 
their infants; and (4) treatment, care, and support for infected mothers and children. 
Beginning in June 2011, PEPFAR’s efforts have been framed around the Global Plan 
Toward Elimination of New HIV Infections Among Children by 2015 and Keeping Their 
Mothers Alive.1 Co-led by the Joint United Nations Programme for HIV/AIDS (UNAIDS) 
and PEPFAR, this initiative seeks to reduce new pediatric infections by 90% and halve HIV-
related maternal mortality by 2015.
To reach these goals, PEPFAR has worked closely with partners on multiple levels. First, 
PEPFAR has partnered with Ministries of Health to support country-led PMTCT efforts, 
working side-by-side with national staff to build local capacity and plan for program 
sustainability. Much of this collaborative work is formalized in so-called “Partnership 
Frameworks” that emphasize the shared goals and mutual responsibility of bilateral 
commitments.3 Second, PEPFAR has taken a key leadership role in the Global Plan’s 
implementation, which has included serving as co-chair for the Global Steering Group (with 
UNAIDS) and as an active partner in the UNICEF/WHO-led Interagency Task Team on 
Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Children. 
Third, PEPFAR has coordinated its activities with the Global Fund for AIDS, Tuberculosis, 
and Malaria, other donors, and multilateral agencies to minimize programmatic overlap and 
to maximize efficiencies on the ground. It has also developed active partnerships with the 
private sector to leverage financial resources and core competencies with an emphasis on 
laboratory system strengthening, improved commodity distribution, and management 
capacity building. Fourth, PEPFAR technical teams have helped to develop generic tools (eg, 
clinical curricula, job aids, and training manuals4) that have been adapted and implemented 
in many settings. Finally, PEPFAR has provided direct support for PMTCT program scale-
up through the provision of technical assistance and financial resources to governments, 
nongovernmental organizations, and civil society organizations for implementation and 
evaluation of evidence-based PMTCT interventions. In fiscal years 2009–2011, PEPFAR’s 
investments in PMTCT totaled over $940 million, with annual budgets increasing each year. 
This total includes supplemental funds to accelerate PMTCT scale-up in 14 high-burden 
countries: $100 million in fiscal year 2010 and $180 in fiscal year 2011.
CHALLENGES AND OPPORTUNITIES IN PROGRAM IMPLEMENTATION
Increasing Coverage Through PMTCT Service Scale-Up
An important focus of most national programs has been the rapid expansion of services, in 
an effort to maximize population coverage of PMTCT interventions. The congressional 
authorization for PEPFAR sets explicit coverage targets for HIV testing and counseling of 
pregnant women (80%) and for providing antiretroviral drugs to those diagnosed with HIV 
(85%). To date, progress at the national level has varied in the 22 countries prioritized for 
virtual elimination of mother-to-child transmission (Fig. 2). Given the collaborative nature 
of PMTCT scale-up–in which PEPFAR is one donor partner among numerous actors—its 
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direct contribution to these coverage targets is difficult to quantify. However, PEPFAR 
support has resulted in steadily decreasing numbers of new infant HIV infections (Fig. 3), 
and the program is on track to meet its target of directly supporting the provision of 
antiretroviral prophylaxis and/or therapy to 1.5 million HIV-infected pregnant women 
cumulatively in 2012 and 2013 (Fig. 4).
One critical obstacle to high population coverage is that many women may not seek 
antenatal services at health institutions and are therefore missed by facility-based 
interventions. In Ethiopia, for example, an estimated 72% of pregnant women never access 
antenatal care at a health facility. Even in countries where at least 1 antenatal clinic visit is 
common—including Zambia (94%), Malawi (92%), and Zimbabwe (90%)—rates of repeat 
clinic visits and institutional delivery decrease considerably.5 PEPFAR has supported several 
innovative approaches to increase uptake of PMTCT services in the face of such challenges, 
including extension of HIV testing into the community and engagement of community 
health workers and peer supporters to link patients to facilities and retain them in care.6–8 
Such strategies can also improve overall maternal and child health, by broadening their 
scope outside of HIV and linking patients to other health services.
Reducing Mother-to-Child Transmission Through More Efficacious Regimens
Over the past decade, a steady stream of new discoveries has advanced the standards of HIV 
prophylaxis and treatment for pregnant and lactating women, and their breastfeeding infants. 
Since the original WHO PMTCT guidelines were published in 2000, the recommended 
duration and complexity of antiretroviral prophylaxis has steadily increased, with present 
recommendations now aimed specifically at the discrete antenatal, intrapartum, and 
postnatal risk periods. Initiating treatment-eligible women on antiretroviral treatment (ART) 
as early as possible in pregnancy has been incorporated as a priority intervention. With the 
demonstration of reduced postpartum transmission when mothers or infants are given 
antiretroviral regimens during breastfeeding,9–14 infant feeding guidance has moved toward 
longer breastfeeding durations to improve HIV-free survival. Properly implemented, the 
2010 WHO guidelines for PMTCT could result in mother-to-child transmission rates of 
<5%, a figure that moves closer to the accomplishments of North America and Europe.15,16 
However, implementation has been imperfect. Fragile health systems that struggled to 
provide the simplest PMTCT regimens (ie, peripartum single-dose nevirapine) have been 
asked to provide substantially more complex antiretroviral interventions. In this respect, 
many countries have grappled with how best to align expansion of PMTCT services to the 
rapid expansion of HIV treatment. PEPFAR’s investments in health systems—including 
human resources, supply chain, and laboratory capacity—have led to improved and more 
efficient clinical systems. Although data are limited, there is evidence that the quality of 
PMTCT services, including the provision of more efficacious regimens, has improved 
alongside increasing service coverage.17
Establishing a Continuum of Care: PMTCT to HIV Care and Treatment
PMTCT represents a unique and convenient entry point for HIV care and treatment services, 
not only for women and their infants but also for sexual partners and other family members. 
HIV prevalence among antenatal attendees is typically higher than that found in the general 
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population and, when services are available, HIV testing is often accepted at near universal 
rates.18 The initiation of ART among treatment-eligible women in this context benefits both 
the mother and infant. Based on data from the Zambia Exclusive Breastfeeding Study 
(which was conducted before the widespread availability of ART), initiation of ART at the 
currently recommended CD4 threshold of ≤350 cells per microliter could reduce 88% of 
perinatal and postnatal infections and 92% of maternal deaths.19 Initiation of ART also has 
benefits in reducing horizontal HIV transmission to seronegative partners. Several studies 
have shown that, when their HIV-infected partner initiated ART at the <250 cells per 
microliter CD4 threshold, the risk of horizontal transmission to HIV-negative index patients 
was nearly eliminated.20–22 The pivotal HPTN 052 trial demonstrated similar results when 
ART was started at higher CD4 counts as well. The immediate ART initiation among 
individuals with CD4 cell counts in the 350–550 cells per microliter range resulted in a 
dramatic 96% reduction in horizontal HIV transmission among seronegative partners.23
Although the establishment of a continuum of care between PMTCT and HIV treatment 
services is a recognized priority, it has proven logistically difficult to link the services in 
many settings. In a review of 4 South African clinics, for example, Stinson et al24 found that 
only 51% of treatment-eligible patients initiated ART; the remaining received less effective 
antiretroviral prophylaxis (27%) or no regimen at all (22%). Successful linkages may be 
constrained by physical distances and transport costs, particularly when provision of ART is 
restricted to centralized facilities that are separate from antenatal services. Even when 
services are colocated in the same clinic or hospital, scheduling difficulties and lengthy 
waiting times may serve as disincentives for seeking care.
These bottlenecks can be at least partially addressed with integrated PMTCT-ART service 
models. Killam et al25 demonstrated a 2-fold increase in ART initiation among treatment-
eligible women when services were integrated in the antenatal setting compared with a 
referral-based system. However, the absolute uptake within 60 days of CD4 screening was 
low in both comparison arms (32.9% vs. 14.4%; p<0.05).25 Promising strategies that could 
further boost performance of these integrated health systems include the incorporation of 
point-of-care CD4 assays and use of simplified treatment algorithms (eg, Option B or B+; 
below). Similar approaches could also improve the linkages between early infant diagnosis 
(which generally occurs in postnatal or well-child clinics, under the purview of PMTCT 
programs) and pediatric HIV care and treatment services.26 Results from the CHER study 
demonstrated the significant reduction in mortality associated with immediate initiation of 
ART for infants infected around the time of birth27; the tragedy of HIV transmission from 
mother to infant should not be compounded by missed opportunities to improve child 
survival.
Supporting Innovative But Simplified Policy Approaches to PMTCT
In its 2010 guidelines, the WHO endorsed 2 different strategies that seem to have similar 
efficacy for PMTCT among breastfeeding mothers not yet eligible for ART (defined as CD4 
>350 cells/μL). Both approaches recommend initiation of prophylaxis as early as 14 weeks 
gestation and continuation until the end of breastfeeding. With “Option A,” HIV-infected 
pregnant women initiate zidovudine antenatally, receive single-dose nevirapine, zidovudine, 
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and lamivudine during labor, and zidovudine and lamivudine for 1 week postpartum; their 
exposed infants then receive daily nevirapine through the breastfeeding period (or for 6 
weeks if not breastfeeding).9–12 In contrast, “Option B” involves initiation of maternal triple 
antiretroviral prophylaxis during pregnancy with continuation until breastfeeding 
stops12–14,28–30; infants receive daily nevirapine or zidovudine for the first 6 weeks of life.
The 2010 WHO guidelines did not indicate a preference for either Option A or Option B, 
citing them as comparable strategies to be considered at the country level based on cost, 
feasibility, and acceptability. Certain national guideline modifications, however, have 
generated increased global interest in the use of maternal triple antiretroviral drug regimens 
during pregnancy and breastfeeding.31 In the newest Zambian national guidelines, HIV-
infected members of serodiscordant couples are considered ART eligible, regardless of their 
CD4 cell count or disease stage.32 The Malawian Ministry of Health, recently followed by 
Haiti and Rwanda, have adopted policies to initiate life-long ART for all HIV-infected 
pregnant women, irrespective of CD4 count, in what has been termed “Option B+.”33,34 
Without the need for CD4 screening to determine treatment eligibility—a step associated 
with significant delay and attrition35—this novel strategy is expected to allow initiation of 
therapy earlier in gestation and perhaps further reduce transmission rates. The initiation of 
ART earlier in the course of HIV disease will also reduce the risk of opportunistic infections 
among index patients and prevent horizontal HIV transmission to discordant partners.23,36 
Given known association between maternal survival and infant well being,37,38 such 
strategies likely have important downstream benefits of reducing infant and child morbidity 
and mortality as well.
In April 2012, WHO issued a technical update to describe the possible clinical and 
programmatic advantages to the Option B or B+ approaches for PMTCT, particularly where 
laboratory infrastructure for antenatal CD4 testing is limited. These benefits include 
simplification and streamlining of antiretroviral regimens and service delivery, possible 
harmonization with ART programs, timely initiation of ART among treatment-eligible 
women, and potential to prevent sexual transmission to serodiscordant partners.39 However, 
concerns about adherence and retention, health system demands, and diversion of resources 
away from the sicker patient populations must be carefully studied and systematically 
addressed. Pharmacovigilance systems are needed to monitor the safety of in utero ART 
exposures in infants, particularly when efavirenz-based regimens are used. Animal models 
raised concern of possible teratogenicity with efavirenz in the first trimester. Although 
available data in humans does not demonstrate an increase in population-level risk, direct 
comparison has have not been made to unexposed populations. Finally, cost considerations 
must be carefully deliberated at the country level. Innovative policies like Option B+ have 
the potential for cost-savings over time, despite the large investments that may be required 
initially. Their implementation should leverage additional resources for HIV prevention, 
care, and treatment and not exacerbate funding gaps that may already exist in resource-
constrained settings.
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THE NEED FOR ROBUST PROGRAM EVALUATION
Evaluating Programs Using the PMTCT Cascade
Despite the numerous clinical advancements over the past decade, there remains a 
substantial gap between clinical trial efficacy and “real world” program effectiveness. To 
benefit optimally from proven interventions, patients must successfully navigate a critical 
path including (but not limited to): being offered and accepting HIV testing, receiving a 
positive result, being offered and agreeing to appropriate antiretroviral prophylaxis, and 
adhering to the prescribed regimen.40Ideally, all pregnant women seeking antenatal care 
would move along this “cascade” without complication; in reality, however, significant 
attrition occurs at each step. Barker et al41 demonstrated the potential impact of attrition on 
perinatal HIV transmission using a three-step model. Individuals who successfully navigated 
the cascade would receive optimal benefit (ie, greatest reduction in transmission risk). 
Depending on the point of attrition, patients would receive either partial or no benefit from 
the intervention itself, which would in turn lead to increases in infant HIV transmission at 
the population level. For example, at full coverage, provision for triple antiretroviral 
regimens antenatally (for either prophylaxis or treatment) resulted in an estimated 6-week 
infant HIV transmission of 1.0%. However when the “system efficiency” (ie, retention at 
each step) dropped to 80%—a more realistic estimate for most programs—infant 
transmission at the population level climbed to 6.8%.41 Ciaranello et al42 demonstrated 
similar changes in infant HIV transmission when different model estimates for uptake were 
incorporated across the antenatal and postpartum PMTCT cascade.
A detailed understanding of the PMTCT cascade—tailored to the local context—could prove 
useful to national program managers, because the identification of bottlenecks is an 
important first step for improving performance. Register-based indicators have been used to 
reconstruct steps along the cascade, but for a variety of reasons these data have typically 
proven unreliable.43,44 The PEARL Study included a facility-based cord blood surveillance 
methodology to evaluate nevirapine-based PMTCT programs in Zambia, South Africa, Cote 
d’Ivoire, and Cameroon.45–47 Its findings were notable for the significant heterogeneity that 
existed across facilities when the causes of failed coverage were considered. There is 
unlikely to be a “magic bullet” to improve program performance globally; instead, careful 
monitoring and quality improvement initiatives are needed, tailored to the specific 
challenges of each site.
Understanding the Population Impact of PMTCT Programs
Measuring the impact of PMTCT programs at the population level has proven challenging. 
UNAIDS, PEPFAR, and others have relied heavily on mathematical modeling to estimate 
trends in pediatric HIV incidence, using coverage rates of PMTCT services and other 
national indicators of the epidemic.48 Although this methodology has been refined over 
time, modeling approaches invariably fail to completely incorporate important individual-
level covariates, such as maternal immunologic status, timing of initiation, and adherence. 
These factors contribute significantly to eventual infant outcomes but are largely unavailable 
at a population level.
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Recognizing these limitations, PEPFAR and UN agencies have supported national 
governments to develop and implement approaches that directly measure the impact of 
PMTCT programs on HIV transmission rates and HIV-free survival at the population level.49 
The South African PMTCT program, for example, completed its first national survey of 
PMTCT effectiveness on perinatal HIV transmission by testing 4–8 week old infants for 
HIV exposure and infection at immunization clinics across 9 provinces in 2010. Overall, 
3.5% of HIV-exposed infants were perinatally infected at the population level.50 Although 
the initial evaluation was not designed to measure breastfeeding transmission, the same 
survey has been repeated in 2011 and 2012, and all HIV-exposed infants are being followed 
through 18 months of age to assess overall HIV transmission rates (through the 
breastfeeding period) and HIV-free survival at the population level. PEPFAR-funded 
projects have also studied the feasibility of community survey approaches to describe 
population impact of PMTCT programs. The PEARL Study included a community survey 
component that closely followed the Demographic and Health Surveys regularly conducted 
in many African countries, with the chief modification of linked maternal and infant HIV 
testing.40,51 When implemented in 25 communities across the 4 target countries, infant HIV-
free survival was found to be 80% at 2 years of life.52 A similar approach has been used in 
Rwanda to evaluate its national PMTCT program.53 Although these approaches demonstrate 
great promise—and tools are now being developed to facilitate their implementation on a 
wider scale—work is needed to establish the accuracy and validity of the health outcome 
measurements, particularly at the national level.
TOWARD THE ELIMINATION OF NEW PEDIATRIC HIV INFECTIONS
The bold targets for new Global Plan have reframed the policy discussion around PMTCT,1 
indicating that ending pediatric HIV is something that can and must be achieved. Although 
this vision is laudable—and in fact, has leveraged substantial political will and donor 
investments globally—the question remains as follows: are these goals attainable? Early 
mathematical models highlight the ambitious nature of these targets. Mahy et al54 used the 
SPECTRUM model to estimate overall reductions in mother-to-child HIV transmission 
using several comparison scenarios across 25 countries. Even under the most optimistic 
assumptions—90% coverage for the 2010 WHO guidelines, 50% reduction of incident HIV 
infection among all women, fulfillment of all unmet contraceptive need, and restriction of 
breastfeeding to 12 months—outcomes would still fall short of the goal set for virtual 
elimination. In this scenario, transmission globally would be 8% and new pediatric HIV 
infections would number 72,000 in 2015, representing a 79% reduction from 2009 estimates.
54 Work by Ciaranello et al42 also estimates that, even with 95% uptake of the WHO 
guidelines, projected transmission risk with Option A or B (6.1%–7.7%) would still not 
meet the “virtual elimination” goal of <5%.42 These findings, like those of most 
mathematical models, are heavily reliant on key assumptions, which carry a degree of 
imprecision at the national and regional levels. These models also emphasize reductions in 
new pediatric HIV infections; however, the benefit associated with certain interventions (eg, 
restricted breastfeeding where nutritional supplementation may be limited) must be carefully 
weighed against their potential harm. If we are to make significant gains toward the 
unprecedented goal of virtual elimination—and at the same time maximize maternal and 
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infant survival—a transformative, global approach to PMTCT and maternal-child health will 
be required.
We call for prioritization of 5 key areas. First, the 2010 WHO PMTCT guidelines must be 
implemented without delay. Novel strategies for the rapid and safe initiation of ART among 
eligible pregnant women require urgent evaluation. These may include point-of-care CD4 
testing—which can reduce time between specimen collection, results reporting, and regimen 
initiation55—and treatment strategies (eg, Option B+) that reduce laboratory requirements 
before ART initiation, simplify regimens, and capitalize on antenatal care as an entry point 
into life-long care and treatment. (NB: although innovative approaches such Option B+ may 
remove the need for prerequisite CD4 screening, access to high quality laboratory services 
remains important for the long-term monitoring of treatment response.) The increased 
demand for antiretroviral prophylaxis and treatment will require further targeted support for 
health care infrastructure, and sustained investment in commodity distribution, human 
resource development, and monitoring and evaluation. Task shifting of routine HIV care and 
treatment to mid-level providers, and counseling and support services to community cadre or 
peer counselors, will play important roles in these efforts.56,57 Leveraging synergies between 
HIV services and key maternal, child, and neonatal care will be necessary to enhance 
PMTCT access and reduce mortality in these populations.56,57 Programs should also identify 
and evaluate innovative ways to extend programmatic reach into communities, so groups 
that do not typically access facility-based care gain access to PMTCT services.
Second, tailored approaches for patient retention and adherence are needed, for both women 
on prophylaxis and on life-long treatment. Program attrition has been recognized as an 
important threat to the long-term success of adult HIV treatment,58–60 and early studies 
suggest that rates of follow-up losses may be higher when women start ART during 
pregnancy.61,62 In a meta-analysis of 51 studies—including over 20,000 HIV-infected 
pregnant and postpartum women—74% had adequate adherence (defined as >80%) to their 
regimen; however, adherence was significantly lower in the postpartum than antepartum 
period (52% vs. 70%).63 Suboptimal adherence to medications and clinic visits will reduce 
the effectiveness of prophylaxis or treatment for PMTCT and could even lead to the 
transmission of resistant virus from mother to infant.64,65 Additionally, women who initiated 
ART for their own health, but interrupt treatment, face a more than 2-fold increased risk of 
disease progression.66 Novel models, such as partner-based support and community-based 
distribution of antiretroviral drugs, should be rigorously evaluated and considered for wider 
implementation.
Third, we must redouble our efforts to protect parents from HIV acquisition. HIV incidence 
remains unacceptably high in many settings,67–69 and a new maternal HIV infection during 
pregnancy poses greater risk for transmission to the infant.70,71 Partner-based HIV testing is 
an important first step in such efforts. Couples identified as discordant may benefit from 
several biomedical interventions such as vaginal microbicide prophylaxis, antiretroviral pre-
exposure prophylaxis, male circumcision, and ART provided for the dual purposes of 
treatment and prevention (“treatment as prevention”).23,72–76 We must devise clinical care 
strategies that incorporate partners if PMTCT is to truly function as an entry point for 
family-based care.
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Fourth, the unmet need for family planning must be addressed globally, particularly among 
HIV-infected women. Prevention of unintended pregnancies is a highly cost-effective tool 
for decreasing the pediatric HIV burden and for reducing maternal deaths, both related and 
unrelated to HIV disease.77–79 Strategies are needed to address barriers to access and to 
support its integration into HIV care and treatment.80,81 Further research is also needed to 
elucidate the complicated relationship between certain hormonal contraceptive methods (eg, 
injectable progestins), HIV acquisition, and HIV disease progression.82 Until definitive data 
are available, however, the magnitude of benefit from family planning clearly outweighs its 
potential risk, particularly when used in conjunction with barrier methods (ie, dual method 
use).
Finally, although access to PMTCT services should remain a goal of programs worldwide, 
we must recognize the limitations of the simple coverage metric in describing direct health 
impact. In parallel, countries should focus on promising strategies for measuring infant HIV 
infection and HIV-free survival at the population level, such as household surveys and/or 
immunization clinic-based evaluations with long-term infant follow-up. Such population-
based methods must be evaluated for acceptability and feasibility, validated in their ability to 
reliably measure maternal and infant health outcomes, and implemented broadly and 
regularly to determine gains in PMTCT effectiveness. These methods will be critical to 
ensuring that interventions aimed at preventing transmission do not negatively impact AIDS-
free maternal or child survival, as these are the ultimate goals of a comprehensive PMTCT 
program.
In conclusion, the incremental scientific discoveries of the past several years have 
culminated in the development of an evidence-based strategy for combination HIV 
prevention, one that has been supported by PEPFAR and others.83 Policymakers and 
program implementers now have a full armamentarium of interventions, including PMTCT, 
male circumcision, HIV treatment for eligible individuals, and ART for HIV-infected 
members of serodiscordant couples. If properly coordinated and fully implemented at scale, 
this “combination prevention package” can dramatically reduce the burden of HIV disease 
and lead us to an AIDS-free generation. The elimination of new pediatric HIV infections and 
the improvement of maternal and infant survival are cornerstones of this vision. In 
collaboration with national governments, multilateral organizations, donors, and civil 
society, PEPFAR’s sustained commitment and leadership are critical to realizing this 
ambitious goal in the years to come.
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Important policy and program milestones in the PMTCT, 1999–2012. PMTCT, prevention of 
mother-to-child transmission of HIV.
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National coverage of HIV testing among all pregnant women and antiretroviral provision 
among HIV-infected pregnant women in 22 high priority countries for EMTCT in 2010. 
*Indicates that national coverage estimates not yet available. Adapted from the Joint United 
Nations Programme on HIV/AIDS (UNAIDS), Global HIV/AIDS update: epidemic update 
and health sector progress towards universal access, progress report 2011. EMTCT, 
eliminating mother-to-child HIV transmission.
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Modeled estimates of infant HIV infections averted through PEPFAR-supported programs, 
2004–2011. Between 2004 and 2010 (shaded grey), modeling was based on the effectiveness 
of single-dose nevirapine regimen only because disaggregated data regarding prescribed 
regimens were not routinely collected. Starting in 2011, detailed data about prescribed 
regimens were collected across all supported countries. The estimate from 2011 (shaded 
black) takes into account the decreased risk of transmission with more efficacious regimens.
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Number of pregnant women placed on antiretroviral prophylaxis or treatment and the 
corresponding annual program funding across 22 high priority countries for EMTCT, 2004–
2011. EMTCT, eliminating mother-to-child HIV transmission.
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